Cardiotropic formulation
OwnerNikolai V. Karsanov, Galina V. Sukoian +5inventors
InventorsNikolai V. Karsanov, Galina V. Sukoian, Zinaida G. Khugashvili, Dali R. Tatulashvili, Evgenia V. Selikhova, Nodar N. Kipshidze, Eteri I. Guchua
Life of this patent
Estimating the term…
Abstract
The invention provides a cardiotropic formulation comprising a cardiac glycoside, a beta-adrenergic receptor stimulant nicotinamide adenine dinucleotide, cytochrome C and inosine for use in conditions of heart failure.
Claims14
An improved cardiotropic composition containing a cardiac glycoside and .beta.-adrenergic receptor stimulant wherein the improvement comprises the inclusion of nicotinamide adenine dinucleotide, cytochrome C and inosine, wherein the composition comprises by parts by weight:
- ______________________________________ cardiac glycoside 0.05-0.2 adrenergic receptor stimulant 0.3-3.5 selected from oxyfedrine and nonachlazin nicotinamide adenine dinucleotide 0.5-5 cytochrome C 5-15 inosine 20-250, ______________________________________
- and pharmaceutically acceptable carriers and diluents.
A cardiotropic formulation comprising a cardiac glycoside selected from the group consisting of .beta.-acetyldigoxin, .beta.-methyldigoxin and strophanthin K;
- a .beta.-adrenergic receptor stimulant selected from the group consisting of oxyfedrin and nonachlazin;
- nicotinamide adenine dinucleotide;
- cytochrome C and inosine, wherein the composition comprises by parts by weight;
- ______________________________________ cardiac glycoside 0.05-0.2 adrenergic receptor stimulant 0.3-3.5 nicotinamide adenine dinucleotide 0.5-5 cytochrome C 5-15 inosine 20-250 ______________________________________
- and pharmaceutically accepted carriers and diluents.
A method for simultaneous restoration of ATP production, transmembrane calcium transport and the cardiomyocyte contraction--relocation system which comprises administering to a patient suffering from disruption of one or more of these mechanisms a dose effective to restore said mechanisms of a composition comprising:
- a cardiac glycoside a .beta.-adrenergic receptor stimulant, nicotinamide adenine dinucleotide, cytochrome C and inosine, wherein the composition comprises by parts by weight:
- ______________________________________ cardiac glycoside 0.05-0.2 adrenergic receptor stimulant 0.3-3.5 selected from oxyfedrine and nonachlazin nicotinamide adenine dinucleotide 0.5-5 cytochrome C 5-15 inosine 20-250, ______________________________________
- and pharmaceutically acceptable carriers and diluents.
Dependencies are inferred from the claim text.